Clinical Trials Browser

Phase 2/3 × Myeloid × 30 days × Clear all

NCT04910685 2026-04-06

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2/3 Recruiting

534 enrolled

Myeloid

Mastocytosis, Systemic

NCT04256317 2026-04-03

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic